Jan 8, 2013
Top 25 M&A Deals of 2012
Who bought who last year? Find out here.
Big bucks were spent on M&As last year. Read on to find out which deal was worth the most. [© Ben Chams - Fotolia.com]
(Page
2
of
2)
#12. Ardea
Acquired by: AstraZeneca
Price: $1.26 billion
Deal Completed: June 19
Premium: 54%
#11. Fougera
Acquired by: Novartis
Price: $1.525 billion
Deal Completed: July 23
Premium: N/A
#10. Par Pharmaceuticals
Acquired by: TPG Capital
Price: $1.9 billion
Deal Completed: Sept. 28
Premium: 37%
#9. Dako
Acquired by: Agilent Technologies
Price: $2.2 billion
Deal Completed: June 21
Premium: N/A
#8. Inhibitex
Acquired by: Bristol-Myers Squibb
Price: $2.5 billion
Deal Completed: Feb. 13
Premium: 163%
#7. Medicis
Acquired by: Valeant Pharmaceuticals
Price: $2.6 billion
Deal Completed: Dec. 11
Premium: 39%
#6. Boston Biomedical
Acquired by: Dainippon Sumitomo Pharma
Price: $2.63 billion9
Deal Completed: April 24
Premium: N/A
#5. Human Genome Sciences
Acquired by: GlaxoSmithKline
Price: $3 billion
Deal Completed: Aug. 3
Premium: 99%
#4. Gen-Probe
Acquired by: Hologic
Price: $3.8 billion
Deal Completed: Aug. 1
Premium: 20%
#3. Amylin Pharmaceuticals
Acquired by: Bristol-Myers Squibb
Price: $5.3 billion10
Deal Completed: Aug. 8
Premium: 101%
#2. Actavis Group
Acquired by: Watson Pharmaceuticals11
Price: $5.547 billion11
Deal Completed: Oct. 31
Premium: N/A
#1. Pharmasset
Acquired by: Gilead Sciences
Price: $11.2 billion
Deal Completed: Jan. 17
Premium: 90%
Notes:
1 Upsher-Smith agreed to pay Proximagen £223 million up-front plus up to £133.8 million tied to development milestones for two drug candidates, obesity drug PRX00933 and a VAP-1 antagonist for rheumatoid arthritis. Figures converted to USD via XE on Jan. 3, 2013.
2 Figures converted from announced purchase price of £367 million via XE on Jan. 3, 2013. Cinven said Oct. 15 it planned over time to merge Amdipharm with Mercury Pharma.
3 Sun has offered to acquire, at $39.50 per share, the remaining 33.5% of Taro shares not already owned by Sun.
4 Jazz Pharmaceuticals agreed to pay Eusa Pharma $650 million up-front, about $30 million up-front toward working capital, cash and certain liabilities; plus an up-to-$50 million milestone payment tied to lead product Erwinaze™ (asparaginase Erwinia chrysanthemi) achieving an undisclosed U.S. net sales target in 2013.
5 Converted from announced purchase price of £465 million via XE on Jan. 3, 2013. Cinven acquired Mercury Pharma from Hg Capital Trust.
6 Takeda agreed to pay URL Pharma $800 million upfront, plus an undisclosed amount in milestone payments related to performance.
7 Converted from announced purchase price of EUR NOK 4.845 billion via XE on Jan. 3, 2013. On Dec. 20, 2012, BASF said it would extend its offer for ProNova BioPharma until Jan. 18, 2013.
8 Celgene agreed to pay Avila Therapeutics $350 million up-front, plus up to $575 million in milestone payments related to AVL-292, a Bruton’s tyrosine kinase inhibitor candidate, and candidates from Avila’s discovery program.
9 Dainippon Sumitomo agreed to pay Boston Biomedical $200 million up-front, up to $540 million in development milestone payments for its two clinical-stage programs—BBI608 for colorectal cancer and BBI503 for advanced solid tumors—and up to $1.89 billion in milestone payments tied to achievement of several undisclosed net sales targets, the last payment tied to net sales of greater than $4 billion in any fiscal year.
10 The value of the deal swells to $7 billion when Amylin's net debt and a contractual payment obligation to Eli Lilly & Co. totaling $1.7 billion are included.
11 Watson changed its name to Actavis on Jan. 1, 2013. Figures converted from announced purchase price of €4.25 billion via XE on Jan. 3, 2013.